Veracyte Stock Alpha and Beta Analysis
| VCYT Stock | USD 31.51 1.08 3.55% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Veracyte. It also helps investors analyze the systematic and unsystematic risks associated with investing in Veracyte over a specified time horizon. Remember, high Veracyte's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Veracyte's market risk premium analysis include:
Beta 1.13 | Alpha (0.31) | Risk 3.58 | Sharpe Ratio (0.13) | Expected Return (0.46) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Veracyte |
Veracyte Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Veracyte market risk premium is the additional return an investor will receive from holding Veracyte long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Veracyte. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Veracyte's performance over market.| α | -0.31 | β | 1.13 |
Veracyte expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Veracyte's Buy-and-hold return. Our buy-and-hold chart shows how Veracyte performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Veracyte Market Price Analysis
Market price analysis indicators help investors to evaluate how Veracyte stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Veracyte shares will generate the highest return on investment. By understating and applying Veracyte stock market price indicators, traders can identify Veracyte position entry and exit signals to maximize returns.
Veracyte Return and Market Media
The median price of Veracyte for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 41.18 with a coefficient of variation of 10.33. The daily time series for the period is distributed with a sample standard deviation of 4.16, arithmetic mean of 40.31, and mean deviation of 3.17. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 4347 shares by Annie McGuire of Veracyte at 24.0 subject to Rule 16b-3 | 12/20/2024 |
2 | Disposition of 10000 shares by Eastham Karin of Veracyte at 5.28 subject to Rule 16b-3 | 01/02/2025 |
3 | HSIC Stock Might Rise Following the Acquisition of Acentus | 01/16/2025 |
4 | Disposition of 6112 shares by Rebecca Chambers of Veracyte at 24.0 subject to Rule 16b-3 | 01/23/2025 |
5 | Disposition of 527 shares by Rebecca Chambers of Veracyte at 43.85 subject to Rule 16b-3 | 02/03/2025 |
6 | New Study Shows Veracytes Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer | 02/05/2025 |
7 | Veracyte Inc Showcases New Data on Cancer Diagnostics at ASCO GU Symposium | 02/14/2025 |
8 | Veracyte Q4 Earnings and Revenues Beat Estimates | 02/24/2025 |
9 | Veracyte Inc Q4 2024 Earnings Call Highlights Record Revenue Growth and Strategic ... | 02/25/2025 |
10 | Veracyte Full Year 2024 Earnings EPS Misses Expectations | 02/26/2025 |
11 | Veracyte Price Target Raised to 49.00 | 02/28/2025 |
12 | Disposition of 7000 shares by Annie McGuire of Veracyte at 33.84 subject to Rule 16b-3 | 03/03/2025 |
13 | Disposition of 1142 shares by Annie McGuire of Veracyte at 33.6922 subject to Rule 16b-3 | 03/04/2025 |
14 | Acquisition by Marc Stapley of 90601 shares of Veracyte subject to Rule 16b-3 | 03/06/2025 |
15 | Veracyte Stock Surges 45.6 percent in a Year Whats Driving the Rally | 03/13/2025 |
About Veracyte Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Veracyte or other stocks. Alpha measures the amount that position in Veracyte has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Days Sales Outstanding | 54.18 | 40.82 | 38.1 | 34.7 | PTB Ratio | 1.58 | 1.91 | 2.61 | 2.48 |
Veracyte Upcoming Company Events
As portrayed in its financial statements, the presentation of Veracyte's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Veracyte's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Veracyte's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Veracyte. Please utilize our Beneish M Score to check the likelihood of Veracyte's management manipulating its earnings.
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Veracyte
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Veracyte Stock Analysis
When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.